Company news

HLS Therapeutics, Inc. news in 2025

HLS Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

November 18, 2025

HLS Therapeutics Announces Q3 2025 Financial Results

November 13, 2025

HLS Therapeutics to Host Q3 2025 Financial Results Conference Call

October 30, 2025

HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

October 14, 2025

HLS Therapeutics Announces New Credit Agreement

August 20, 2025

HLS Therapeutics Announces Q2 2025 Financial Results

August 14, 2025

HLS Therapeutics to Host Q2 2025 Financial Results Conference Call

July 31, 2025

HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan

July 2, 2025

HLS Therapeutics Reports Annual Meeting Results

June 20, 2025

HLS Therapeutics Announces Q1 2025 Financial Results

May 8, 2025

HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada

May 8, 2025

HLS Therapeutics to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

April 28, 2025

HLS Therapeutics to Host Q1 2025 Financial Results Conference Call

April 24, 2025

HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid

March 13, 2025

HLS Therapeutics Appoints Christine Elliott to its Board of Directors

March 13, 2025

HLS Therapeutics to Host Fiscal 2024 Financial Results Conference Call

February 27, 2025

Calls in 2025

Decks in 2025